Article
Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
Clinical advances in hematology & oncology : H&O - 1 Nov 2008
Gaston Cindy, Kolesar Jill
Abstract excerpt
Tamoxifen has been used as adjuvant hormonal therapy for estrogen receptor positive breast cancer for over 30 years and is also widely used for the treatment of metastatic breast cancer. Tamoxifen is metabolized to its more active form by cytochrome P450 2D6 (CYP2D6); decreases in CYP2D6 activity, either by inactivating polymorphisms or drug interactions, can reduce concentrations of tamoxifen's active...
Topics
Join the communities discussing this publication.